Protocol > Research Protocol
Himanshu M, Singh KR, Shougrakpam J
1 July 2018
4. OBJECTIVES
Primary objective
The primary objective of this study is to assess the effectiveness of HCV curative treatments in
patients with chronic hepatitis C (CHC), co-infected with HIV in Manipur, India.
Secondary objectives
a. To describe the demographic, clinical and biological characteristics of patients with chronic
hepatitis C and HIV co-infection
b. To assess the effectiveness of HCV curative strategies in patients with chronic HCV, co-infected
with HIV stratified by regimen and by site
c. To identify risk factors associated with differing virological responses
d. To assess the safety of HCV treatment
e. To monitor the safety of HCV treatment in HIV co-infected patients
f. To document the clinical and biological tolerance of the HCV treatment
g. To assess the feasibility of HCV treatment
h. To assess comparative performance of elastography (Fibroscan®) and APRI (AST to Platelet
Ration Index), to evaluate liver fibrosis among HIV/HCV co-infected individuals
i. To describe causes of non-eligibility for treatment
j. To describe the clinical and biological evolution of co-infected patients, not eligible for HCV
treatment
k. To assess treatment adherence
Primary objective
The primary objective of this study is to assess the effectiveness of HCV curative treatments in
patients with chronic hepatitis C (CHC), co-infected with HIV in Manipur, India.
Secondary objectives
a. To describe the demographic, clinical and biological characteristics of patients with chronic
hepatitis C and HIV co-infection
b. To assess the effectiveness of HCV curative strategies in patients with chronic HCV, co-infected
with HIV stratified by regimen and by site
c. To identify risk factors associated with differing virological responses
d. To assess the safety of HCV treatment
e. To monitor the safety of HCV treatment in HIV co-infected patients
f. To document the clinical and biological tolerance of the HCV treatment
g. To assess the feasibility of HCV treatment
h. To assess comparative performance of elastography (Fibroscan®) and APRI (AST to Platelet
Ration Index), to evaluate liver fibrosis among HIV/HCV co-infected individuals
i. To describe causes of non-eligibility for treatment
j. To describe the clinical and biological evolution of co-infected patients, not eligible for HCV
treatment
k. To assess treatment adherence
Conference Material > Poster
Himanshu M, Lin Oo W, Cavalheiro AP, Mesic A, Shougrakpam J, et al.
MSF Scientific Days International 2020: Research. 20 May 2020
Conference Material > Poster
Mohan Kumar H, Lin Oo W, Gurung P, Spencer H, Shougrakpam J, et al.
MSF Scientific Days International 2021: Research. 18 May 2021
Conference Material > Poster
Himanshu M, Lin Oo W, Cavalheiro AP, Mesic A, Shougrakpam J, et al.
MSF Scientific Days International 2020: Research. 20 May 2020